Abstract
Introduction
Homeland Security (HLS) and Homeland Defense (HLD) activities, both within
government and in the private sector, combine together to create the
technological part of America' s effort to mitigate/protect against threat of
terror attacks. The structure is complex, contains a substantial area of
overlapping responsibilities, many redundancies and duplicate activities, and
has a multitude of R&D projects woven into it.
Providing a security blanket to the population in preventing as well as
minimizing the effects of terror is a complicated task that no single approach
can fully accomplish. Therefore, the government' s strategy comprises of
investing in three complementary technology directions that together will form
a comprehensive security solution:
Advanced Technologies R&D whose goal will be to develop novel means for the
purpose of detecting a terrorist threat before it is being carried out. Such
detection capability will be critical in protecting the population against
CBRNE threats. Novel detection concepts are required all across the spectrum,
as current technologies are inadequate at best.
Pharmaceuticals and Chemicals R&D which is comprised of the development of new
therapeutics and vaccines whose purpose will be to minimize the damage after
an attack takes place. In particular, novel vaccines and drugs that counter
recognized biological terror threats can minimize the damage of such attacks.
Information Technology R&D whose goal will be to develop IT-based technology
that will allow for rapid communication and analysis of HLS-related data. This
third technological thrust is crucial for the both the proper functioning of
emergency response crews after a catastrophic event takes place, as well as
for the recognition that a terror event from an unknown threat is taking
place. The need for networked information technology is critical as neither
detector technology nor the pharmaceuticals that will be developed will be
able to mitigate unknown Emerging Threats. New threats will go undetected by
the automated instruments, and can only be made known if an abnormal amount of
human casualties suddenly reported.
Some of the main questions that this report answers are:
- What is the size of the Federal government' s HLS Pharmaceuticals and
chemicals R&D funding, and which agencies are responsible for performing and
financing Research & Development?
- What are the main Research & Development institutions and organizations
related to HLS Pharmaceuticals and Chemicals R&D?
- What are the main HLS Pharmaceuticals and Chemicals R&D applications; who
sets priorities in this new environment and how?
- What are the specific Pharmaceuticals and Chemicals R&D programs (from all
Federal agencies), and what is the associated funding that has relevancy to
HLS applications?
The report is divided into two major parts:
- Part 1 - a complete description of the entire HLS Pharmaceuticals &
Chemicals R&D activity that is funded by the many participating Federal
agencies. We describe agencies, resources, programs and provide budgetary
overview for trends in R&D funding for Homeland Security and Homeland Defense
markets.
- Part 2 - describes in detail HLS Chemicals & Pharmaceuticals R&D
applications, by mission, the participating funding agencies, categories of
projects funded by each agency, current and future funding of HLS R&D programs
that we were able to find, and an outlook of future R&D Funding Opportunities
activity.
View Cart
